[A report on ocusert (author's transl)].
The fourth communication on the Ocular Therapeutic System Ocusert (Alza Corp., Palo Alto/Calif.; Federal Republic of Germany: Chemie Grünenthal, Stolberg) deals with experiences of a 24 months follow-up study as well as with the results of an omission test. From the diurnal curves carried out over 24 months, and the regression curves the conclusion can be drawn that the continuous application of pilocarpine has not led either to clinically recognisable changes in morphological structures or to a noticeable decreasing sensitivity to the drug so far. The omission test performed with placebo units shows the effect of intraocular pressure reduction remains reversible.
D002940:Circadian Rhythm; D005500:Follow-Up Studies; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D010862:Pilocarpine / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D010919:Placebos
D010919:Placebos; D010862:Pilocarpine
Ocusert, ein neuartiges Medikamententrägersystem für die Glaukombehandlung. 4. Mitteilung